Travere Therapeutics (17R) Income Statement
Travere Therapeutics Income Statement
Last quarter (Q2 2026), Travere Therapeutics's total revenue was $169.58M, an increase of 48.17% from the same quarter last year. In Q2, Travere Therapeutics's net income was $-34.80M. See Travere Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 490.73M | $ 233.18M | $ 145.24M | $ 109.46M | $ 131.84M | |
| $ 480.39M | $ 225.43M | $ 133.79M | $ 105.04M | $ 128.02M | |
| $ 543.21M | $ 549.26M | $ 521.93M | $ 424.85M | $ 327.44M | |
| Depreciation and Amortization | $ 60.74M | $ 43.55M | $ 38.53M | $ 20.72M | $ 12.75M |
| $ 22.22M | $ -265.77M | $ -326.25M | $ -299.42M | $ -184.46M | |
| $ -62.82M | $ -323.83M | $ -388.14M | $ -319.81M | $ -199.43M | |
| $ 13.55M | $ 3.32M | $ 12.03M | $ -11.34M | $ -17.46M | |
| $ -49.27M | $ -320.51M | $ -376.11M | $ -331.15M | $ -216.88M | |
| $ -25.55M | $ -321.55M | $ -111.40M | $ -278.48M | $ -180.09M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.56 | $ -4.08 | $ -1.50 | $ -4.37 | $ -3.01 |
| Diluted EPS | $ -0.56 | $ -4.08 | $ -1.50 | $ -4.37 | $ -3.01 |
| Weighted Average Shares Outstanding | 89.21M | 78.89M | 74.27M | 63.76M | 59.83M |
| Weighted Average Shares Outstanding (Diluted) | 89.21M | 78.89M | 74.27M | 63.76M | 59.83M |
Currency in USD